Specifically, inhibition of binding between programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) has been demonstrated to regain suppressed anti-tumor immunity, which has great potential to effectively treat cancer recurrence in the clinical settings8,9. The gene discussed is PDCD1; the disease is neoplasm.